Seres Therapeutics (MCRB)

• Market cap: $164M
• 1 day: -0.53%
• 5 days: 6.67%
• 1 month: 8.45%
• 3 months: -13.51%
• 6 months: 26.50%
• Year to date: -31.43%
• 1 year: -28.36%
• 5 years: -78.18%
• 10 years: -98.13%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Employees: 233

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

99% more call options, than puts

Call options by funds: $1.21M | Put options by funds: $607K

19% more capital invested

Capital invested by funds: $50.2M [Q2] → $59.9M (+$9.74M) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

3.9% less ownership

Funds ownership: 45.76% [Q2] → 41.86% (-3.9%) [Q3]

18% less funds holding

Funds holding: 93 [Q2] → 76 (-17) [Q3]

41% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 27

65% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 26

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1.25 30% upside
• Avg. target: $5.63 486% upside
• High target: $10 942% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Canaccord Genuity John Newman 52% 1-year accuracy 14 / 27 met price target	942% upside $10	Buy Maintained	14 Nov 2024
Chardan Capital Keay Nakae 31% 1-year accuracy 22 / 72 met price target	30% upside $1.25	Buy Maintained	13 Nov 2024